公开(公告)号：US20140171408A1

公开(公告)日：2014-06-19

申请号：US14185700

申请日：2014-02-20

Applicant: Genentech, Inc.

Inventor： Toby Jonathan Blench ,  Charles Ellwood ,  Simon Charles Goodacre ,  Yingjie Lai ,  Jun Liang ,  Calum MacLeod ,  Steven R. Magnuson ,  Vickie Hsiao-Wei Tsui ,  Karen Williams ,  Birong Zhang

IPC: A61K31/5377 ,  C07D513/04 ,  A61K31/519 ,  A61K31/437 ,  A61K31/501 ,  A61K31/506

CPC classification number: A61K31/5377 ,  A61K31/437 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  C07D513/04

Abstract: Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I.

Abstract translation: 提供式I化合物，立体异构体，互变异构体，溶剂合物，前药和药学上可接受的盐，其中A，X，R 1，R 2，R 4和R 5在本文中定义，药物组合物包括式I化合物和药学上可接受的 载体，佐剂或载体，在治疗中使用化合物或组合物的方法，以及制备式I化合物的方法。

公开(公告)号：US20250114338A1

公开(公告)日：2025-04-10

申请号：US18985513

申请日：2024-12-18

Applicant: Genentech, Inc.

Inventor： Sharada Labadie ,  Jun Liang ,  Daniel Fred Ortwine ,  Xiaojing Wang ,  Jason Zbieg ,  Birong Zhang ,  Simon Charles Goodacre ,  Nicholas Charles Ray ,  Jun Li

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K45/06

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US10280149B2

公开(公告)日：2019-05-07

申请号：US15643808

申请日：2017-07-07

Applicant: GENENTECH, INC. ,  CONSTELLATION PHARMACEUTICALS, INC.

Inventor： Brian K. Albrecht ,  Alexandre Cote ,  Victor Gehling ,  Vickie Hsiao-Wei Tsui ,  James Richard Jr. Kiefer ,  Jun Liang ,  Steven Magnuson ,  Christopher G. Nasveschuk ,  Richard Pastor ,  F. Anthony Romero ,  Alexander M. Taylor ,  Birong Zhang

IPC: C07D401/06 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06 ,  C07D241/04 ,  C07D211/30

Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US10035801B2

公开(公告)日：2018-07-31

申请号：US14775405

申请日：2014-03-13

Applicant: CONSTELLATION PHARMACEUTICALS, INC. ,  GENENTECH, INC.

Inventor： Brian K. Albrecht ,  Steven F. Bellon ,  Victor S. Gehling ,  Jean-Christophe Harmange ,  Kwong Wah Lai ,  Jun Liang ,  Peter Dragovich ,  Daniel F. Ortwine ,  Sharada Labadie ,  Birong Zhang ,  James Richard Kiefer

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/337 ,  A61K31/517 ,  A61K31/437 ,  C12N9/99 ,  C07D498/04 ,  C07D487/14

CPC classification number: C07D487/04 ,  A61K31/337 ,  A61K31/437 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D487/14 ,  C07D498/04 ,  C12N9/99

Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.

公开(公告)号：US09980947B2

公开(公告)日：2018-05-29

申请号：US14972326

申请日：2015-12-17

Applicant: Genentech, Inc.

Inventor： Sharada Labadie ,  Jun Liang ,  Daniel Fred Ortwine ,  Xiaojing Wang ,  Jason Zbieg ,  Birong Zhang ,  Simon Charles Goodacre ,  Nicholas Charles Ray ,  Jun Li

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/138 ,  A61K31/497 ,  A61K31/506 ,  A61K31/565 ,  A61K45/06

CPC classification number: A61K31/437 ,  A61K31/138 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/506 ,  A61K31/565 ,  A61K45/06 ,  C07D471/04

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US09969732B2

公开(公告)日：2018-05-15

申请号：US15481757

申请日：2017-04-07

Applicant: Genentech, Inc.

Inventor： Sharada Labadie ,  Jun Liang ,  Daniel Fred Ortwine ,  Maia Vinogradova ,  Xiaojing Wang ,  Jason Zbieg ,  Birong Zhang ,  Tao Wang

IPC: C07D401/04 ,  C07D217/00 ,  A61K31/4725 ,  C07D471/04 ,  C07D401/12 ,  A61K31/4745 ,  C07D403/12 ,  A61K31/55 ,  C07D401/14 ,  A61K31/5377

CPC classification number: C07D471/04 ,  A61K31/4725 ,  A61K31/4745 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12

Abstract: Described herein are tetrahydroisoquinoline compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituent and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US09505767B2

公开(公告)日：2016-11-29

申请号：US14477566

申请日：2014-09-04

Applicant: Genentech, Inc. ,  Constellation Pharmaceuticals, Inc.

Inventor： Brian K. Albrecht ,  Steven F. Bellon ,  Victor S. Gehling ,  Jean-Christophe Harmange ,  Yves LeBlanc ,  Jun Liang ,  Steven R. Magnuson ,  Vickie Hsiao-Wei Tsui ,  Birong Zhang

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61N5/10

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61N5/10

Abstract: The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20160175289A1

公开(公告)日：2016-06-23

申请号：US14972326

申请日：2015-12-17

Applicant: Genentech, Inc.

Inventor： Sharada Labadie ,  Jun Liang ,  Daniel Fred Ortwine ,  Xiaojing Wang ,  Jason Zbieg ,  Birong Zhang ,  Simon Charles Ray ,  Nicholas Charles Ray

IPC: A61K31/437 ,  A61K31/4545 ,  A61K45/06 ,  A61K31/506 ,  A61K31/565 ,  A61K31/138 ,  C07D471/04 ,  A61K31/497

CPC classification number: A61K31/437 ,  A61K31/138 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/506 ,  A61K31/565 ,  A61K45/06 ,  C07D471/04

Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract translation: 本文描述了具有式I结构的雌激素受体调节活性或功能的四氢 - 吡啶并[3,4-b]吲哚-1-基化合物：及其立体异构体，互变异构体或其药学上可接受的盐，以及取代基和结构特征 在此描述。 还描述了包括式I化合物的药物组合物和药物，以及使用这样的雌激素受体调节剂单独和与其它治疗剂组合用于治疗介导或依赖于雌激素受体的疾病或病症的方法。

公开(公告)号：US20160060267A1

公开(公告)日：2016-03-03

申请号：US14775405

申请日：2014-03-13

Applicant: GENENTECH, INC. ,  CONSTELLATION PHARMACEUTICALS, INC.

Inventor： Brian K. Albrecht ,  Steven F. Bellon ,  Victor S. Gehling ,  Jean-Christophe Harmange ,  Kwong Wah Lai ,  Jun Liang ,  Peter Dragovich ,  Dan Ortwine ,  Sharada Labadie ,  Birong Zhang ,  Jim Kiefer

IPC: C07D487/04 ,  A61K45/06 ,  C12N9/99 ,  A61K31/337 ,  A61K31/517 ,  A61K31/437 ,  A61K31/519 ,  A61K31/5377

CPC classification number: C07D487/04 ,  A61K31/337 ,  A61K31/437 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D487/14 ,  C07D498/04 ,  C12N9/99

Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.

Abstract translation: 提供了可用作一种或多种组蛋白脱甲基酶抑制剂的化合物，例如KDM5。 本发明还提供包含本发明化合物的药学上可接受的组合物和使用本发明组合物治疗各种疾病的方法。

公开(公告)号：US20150065522A1

公开(公告)日：2015-03-05

申请号：US14477566

申请日：2014-09-04

Applicant: Genentech, Inc. ,  Constellation Pharmaceuticals, Inc.

Inventor： Brian K. Albrecht ,  Steven F. Bellon ,  Victor S. Gehling ,  Jean-Christophe Harmange ,  Yves LeBlanc ,  Jun Liang ,  Steven Magnuson ,  Vicki Tsui ,  Birong Zhang

IPC: C07D487/04 ,  A61K45/06 ,  A61N5/10 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61N5/10

Abstract: The present invention relates to compounds formula (I): and to salts thereof, wherein R1-R4 and A have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of histone demethylases, such as KDM5. Also included are pharmaceutically acceptable compositions comprising the compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Abstract translation: 本发明涉及式（I）化合物及其盐，其中R 1 -R 4和A具有说明书中定义的任何值及其组成和用途。 该化合物可用作组蛋白脱甲基酶的抑制剂，例如KDM5。 还包括包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。